IMEP is a chemotherapy regimen that is effective for nasal NK- / T-cell lymphoma.[1] This chemotherapy regimen was also tested in Hodgkin disease as a part of a multidrug alternating scheme COPP / ABV / IMEP. But in that setting it showed no advantage in efficacy and toxicity compared to the use of ABVD or the alternating COPP / ABVD scheme.[2]
Drug regimen
edit| Drug | Dose | Mode | Days |
|---|---|---|---|
| (I)fosfamide | 1500 mg/m2 with mesna | IV infusion | Days 1-3 |
| (M)ethotrexate | 30 mg/m2 | IV bolus | Days 3 and 10 |
| (E)toposide | 100 mg/m2 | IV infusion | Days 1-3 |
| (P)rednisone | 120 mg | PO qd | Days 1-5 |